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Abstract 
Aims/hypothesis: We aimed to test the hypothesis that the effects of dietary sugar on 
lipoprotein metabolism are influenced by non-alcoholic fatty liver disease (NAFLD). 
Methods: The effect of two 12 week, iso-energetic diets, high and low in non-milk extrinsic 
sugars (26% and 6% total energy), matched for macronutrient content, was examined in a 
randomised, cross-over study in men with NAFLD (n=11) and controls (n= 14).  Lipoprotein 
kinetics and the sources of fatty acids for triacylglycerol (TAG) production were measured 
using stable isotope tracers.   
Results: Liver fat was higher after the high versus low-sugar diet in both groups (p<0.02), 
but men with NAFLD showed a relatively greater response than controls (p<0.05). After the 
high versus low-sugar diet, VLDL1-TAG production rate was higher in the controls (p 
<0.002) due to a greater contribution from splanchnic fatty acids (p<0.02) and de novo 
lipogenesis (p <0.002), whereas in NAFLD, VLDL2-TAG production rate was higher (p 
<0.05), due to a greater contribution from splanchnic fatty acids (p<0.02). There was no 
difference in the contribution of systemic NEFA to VLDL1 and VLDL2-TAG production rate 
between diets in either group.  Intermediate density lipoprotein (IDL), LDL2 and LDL3-
apolipoprotein B production rates and post-heparin hepatic lipase activity were all higher 
(p<0.05) on the high-sugar diet in NAFLD.  
Conclusions: A high sugar intake promoted a greater accumulation of liver fat in NAFLD 
than controls and increased VLDL-TAG production in both groups, due mainly to an 
increased contribution of fatty acids from splanchnic sources, which includes hepatic TAG 
storage pools. These effects may drive the formation of atherogenic lipoproteins. 
 
Clinical Trial Registration: NCT01790984 
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Introduction 
A high intake of dietary free sugars, mainly as sugar added to food, can increase cardio-
metabolic risk by promoting adverse changes in plasma lipoproteins, known collectively as 
an atherogenic lipoprotein phenotype (ALP) [1, 2]. This may be influenced by the presence of 
NAFLD which is associated with hypertriglyceridaemia and insulin resistance [3]. 
An elevated plasma concentration of TAG is a pre-requisite for the development of an ALP 
via the remodelling of LDL into small and dense particles with increased potential to promote 
atherosclerosis [4]. Plasma TAG may be increased by an overproduction and secretion of its 
principal transporter, VLDL from the liver, and/or impaired removal of VLDL from the 
plasma via the action of lipoprotein lipase (LPL) [5].  During fasting, the production of 
VLDL-TAG in the liver is mainly regulated by the availability of NEFA from peripheral 
adipose tissue (systemic sources) or splanchnic sources [6]. The latter includes visceral 
adipose tissue, intra-hepatic stores, and the synthesis of fatty acids by de novo lipogenesis 
(DNL) in the liver. Although DNL makes a relatively small contribution to VLDL-TAG 
production, this has been shown to increase substantially when a very high proportion of 
energy is supplied as sugar, especially sucrose and fructose [7]. However, the extent to which 
liver fat affects the handling of hepatic fatty acids in response to sugar intakes representative 
of a Western diet is unknown. This study was designed to test the hypothesis that the 
presence of NAFLD influences the effect of a high sugar versus a low sugar isoenergetic diet, 
on lipoprotein metabolism. 
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Material and Methods 
Participants   
Exclusion criteria were diabetes and any medical condition other than NAFLD, lipid-
lowering medication, unstable weight in the preceding 3 months, and an intake of alcohol 
exceeding 20g/day. Inclusion criteria were men aged 40-65y, BMI 25-30 with raised cardio-
metabolic risk, as assessed by a risk score used previously in the ‘RISCK’ study [8]. Those 
with a raised metabolic score of ≥4 and APO ε3/ε3 genotype, to exclude the confounding 
effects of different apo E isoforms on lipid metabolism, underwent an assessment of intra-
hepatocellular lipid (IHCL) by magnetic resonance spectroscopy (MRS) for assignment to a 
group with NAFLD  [9]  (>5.56%  IHCL, n=11) or low liver fat (Controls) (<5.56% IHCL, 
n=14). All participants provided written informed consent before taking part in the study. The 
study was approved by Surrey Research Ethics Committee (Ref. 08/H1109/227), and 
University of Surrey’s Ethics Committee (Ref. EC/2009/29) and was registered on Clinical 
Trials.gov (NCT01790984).  
 
Study design, dietary interventions and study protocol 
The study had a randomized two-way crossover design, with two dietary interventions. After 
an initial 4 week run-in period on their habitual diet, participants were randomly assigned 
(with a computer-generated sequence of treatments concealed in sealed envelopes) to either 
the high or low sugar isoenergetic diet, with the same macronutrient composition, for 12 
weeks. Participants returned to their habitual diet for 4 weeks, before crossing-over to the 
alternative diet for a further 12 weeks.  During the dietary interventions, participants were 
instructed to maintain their habitual level of physical activity. Body fat, liver fat, lipoprotein 
and lipid kinetics were measured at the end of each diet.  
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Intakes of total carbohydrate and sugar were based on the mean intakes for men aged 40-65 
years in the UK’s National Diet & Nutrition Survey (NDNS), with target intakes for non-milk 
extrinsic sugars (NMES) on the high and low sugar diets corresponding to the upper and 
lower 2.5
th
 percentile of intake in the UK population, respectively [10] . The term NMES, as 
originally defined by the UK’s Department of Health [11], includes free sugars added to food, 
but excludes sugar in whole fruit, and lactose, primarily from cows’ milk [12]. The sugar 
content of the two diets was achieved by a dietary exchange of sugar for starch as described 
in ‘Supplementary material’. Dietary intakes assessed by 3-day diet diaries, (2 weekdays and 
1 weekend day during the run-in period and during the sixth and final week of each dietary 
intervention), were analysed by a single operator using DietPlan 6 (version 6.50, Forestfield 
Software Ltd, UK). 
Metabolic study (Post-diet visits) 
The study design is shown in Supplementary Figure 1. The evening before the metabolic 
study subjects drank 
2
H2O (3g/kg body water, half after the evening meal (standardised low 
fat, low fibre ready-meal) and half at 10pm). They then fasted and drank only water enriched 
with 
2
H2O (4.5g 
2
H2O/liter drinking water). The following morning a blood sample was taken 
to measure deuterium enrichment of palmitate in VLDL1 and VLDL2-TAG and plasma water 
to measure DNL.  A 10h primed constant iv [1-
13
C]leucine infusion (1mg/kg; 1mg/kg/h) 
(99%, Cambridge Isotopes) was administered to measure VLDL1, VLDL2, IDL, LDL2 and 
LDL3-apoprotein B (apoB) kinetics.  An 8h constant iv infusion of [U-
13
C]palmitate (99%, 
Cambridge Isotopes) bound to human albumin (5%, 0.01 µmol.kg
-1
.min
-1
), was administered 
to measure palmitate production rate (assumed to be mainly from systemic adipose tissue 
lipolysis) and the percentage contribution of systemic NEFA to triglyceride export in VLDL1 
and VLDL2. An intravenous bolus of [1,1,2,3,3-
2
H5]glycerol (75µmol/kg) (99%, Cambridge 
Isotopes) was administered to measure VLDL1 and VLDL2-TAG production rate (PR). At 
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varying time intervals as previously reported [13, 14], blood samples were taken to measure 
the enrichment and concentrations of plasma palmitate, αketoisocaproate (αKIC) and 
glycerol, and the enrichment and concentrations of apoB, TAG-palmitate and TAG-glycerol 
in the lipoprotein fractions. At the end of the study, the activity of lipoprotein lipase (LPL) 
and hepatic lipase (HL) were measured in plasma, before and 15 minutes after an intravenous 
injection of 50U/kg heparin.  
Magnetic resonance imaging (MRI) and spectroscopy (MRS) 
Whole body MR images were obtained on a 1.5T Phillips Achieva system (Philips Medical 
Systems, Best, The Netherlands). Volumes of intra-abdominal and subcutaneous abdominal 
adipose tissue were calculated from the abdominal region between the slice containing the 
bottom of the lungs/top of the liver and the slice containing the femoral heads. Spectra were 
analyzed by a single trained observer (ELT) using AMARES. Liver fat was measured relative 
to liver water content as previously described [15].  Seventeen of the 25 participants who 
completed both diets underwent a post-dietary analysis of IHCL and adipose tissue 
distribution by MRS. 
 
Laboratory methods 
VLDL1, VLDL2, IDL, LDL2 and LDL3 were separated by sequential ultracentrifugation [16]. 
Plasma TAG, VLDL1 and VLDL2-TAG were extracted and isotopic enrichment of glycerol 
and palmitate measured as described previously by gas chromatography mass spectrometry 
(GCMS) [13]. The isotopic enrichment of leucine in VLDL1, VLDL2 and IDL-apoB, and 
plasma αKIC enrichment, was measured as described previously by GCMS [14]. Leucine 
enrichment in LDL2 and LDL3-apoB was measured as the N-acetyl, n-propyl-ester derivative 
and analyzed by GC-combustion isotope ratio MS (Delta plus XP isotope ratio mass 
spectrometer, Thermo Scientific). Plasma 
2
H2O enrichment was measured with a Gasbench II 
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inlet system and isotope ratio MS using platinum catalyst rods to liberate hydrogen gas. 
Isotopic enrichment was measured relative to laboratory standards previously calibrated 
against international standards Vienna Standard Mean Ocean Water and Standard Light 
Arctic Precipitation (International Atomic Energy Agency, Vienna, Austria). 
LPL and HL were measured in post-heparin plasma by the Confluolip Lipase test (Progen 
Biotechnik, Heidelberg). Plasma NEFA, total cholesterol, TAG, lipoprotein fraction TAG 
and cholesterol were measured by enzymatic assays using a Cobas MIRA (Roche, Welwyn 
Garden City, UK).  Measurement of plasma adiponectin and leptin were by immunoassay 
(Millipore corporation, Billerica, MA, USA), apoB in lipoprotein fractions by an in-house 
ELISA and oxidised LDL by a commercially available ELISA (Biomedica, GmbH &Co 
Wien, Austria).  Small dense (sd) LDL-cholesterol and plasma apolipoproteins CII, CIII and 
E were measured by precipitation methods (Randox Laboratories Ltd) on an ILab 650 
(Werfen). APO E genotype was determined by quantitative polymerase chain reaction and 
Southern blotting, to exclude carriage of non-Apo Ɛ3 alleles.  
Data analysis 
Tracer enrichment of αKIC, leucine, palmitate and glycerol was expressed as tracer/tracee 
ratio (TTR) corrected for baseline enrichment. Lipoprotein kinetics were calculated using 
compartment models as previously described [13,14]. These models and the calculation of the 
fatty acid contribution to VLDL-TAG PR are shown in the Supplementary material. 
 
Statistical methods  
Data from the end of each dietary period are expressed as arithmetic means for normally 
distributed variables, and log10 transformed geometric means for non-normally distributed 
variables. The natural logarithm of each measurement, for the combined two sets (NAFLD 
and Controls) of the 2-period cross-over data, were analysed as dependent variables in a 
9 
 
general linear mixed model with the following fixed categorical, non-random, explanatory 
effects: treatment period, treatment (low and high sugar), liver fat level (NAFLD and 
Controls) and a treatment by liver fat level interaction, with subject as a model random effect 
using MIXED of SAS Version 9.2 (SAS Institute, Cary, NC, USA). Ratios and 95% 
confidence interval of measurements that were significantly different are shown in the 
Supplementary Material. 
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Results  
Twenty five men completed the study.  The baseline characteristics of both groups, including 
age, body weight, BMI, waist circumference and biochemical measures were similar, except for 
plasma TAG which was 42% higher in men with NAFLD than Controls (p <0.05) (Table 1).  
Dietary intake on high and low sugar diets 
Self-recorded dietary intakes and regular contact with participants indicated that dietary 
compliance was maintained.  There was no difference in reported energy intake between diets 
(Supplementary Table 1). There were also no differences in energy intake, macronutrients 
or alcohol between NAFLD and Controls on either diets. The high sugar diet (26% total 
energy) produced a higher intake of total sugar and NMES in comparison to the baseline and 
low sugar diets (6% total energy) in both groups (p <0.01 for all comparisons).  The high 
sugar diet was lower in starch (p <0.001) than the low sugar diet in both groups. Energy from 
dietary fat intake was significantly lower on the high sugar diet in Controls (p <0.001). 
Change in body weight and plasma lipids 
Body weight was higher after the high versus low sugar diets in NAFLD (p <0.001) and 
Controls (p <0.01) (Table 2). However, there was no difference in body weight between 
NAFLD and the Controls after either diet.  Plasma TAG was higher after the high sugar diet 
relative to the low sugar diet in both groups, but was not statistically significant. Plasma TAG 
was significantly higher in NAFLD relative to Controls after both the high (p <0.01) and low 
sugar diets (p <0.01), respectively.  
Intra-abdominal and subcutaneous adipose tissue, and intra-hepatocellular lipid (IHCL) 
post-diet 
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 Post-dietary IHCL was significantly higher after the high versus the low sugar diet in both 
NAFLD (mean ± SEM, 24.2 ± 6.8% versus 14.2 ± 3.2%, p = 0.01) and Controls (3.7 ± 1.3% 
versus 1.4 ± 0.3% respectively, p <0.01) (Fig 1A). Men with NAFLD showed a greater 
increase in IHCL relative to Controls (p = 0.04). 
Visceral fat and subcutaneous adipose tissue mass was not different between groups, and was 
unaffected by diet in either group (Supplementary Table 2). Post-dietary IHCL was not 
associated with body weight, visceral fat, plasma TAG, or changes in these variables. 
Plasma lipoprotein concentrations and kinetics and post-heparin lipase activities                                            
Between groups Men with NAFLD were distinct from Controls by having higher 
concentrations of VLDL1-TAG and VLDL1-cholesterol, lower VLDL1-TAG fractional 
catabolic rate (FCR) and higher plasma apo-CIII on both the low sugar (p <0.003, p <0.003, p 
<0.05 and p <0.01 respectively) and high sugar diets (p <0.02, p <0.02, p <0.05 and p <0.05) 
(Tables 3, 4 and Supplementary Table 4). On the low sugar diet, NAFLD had higher total 
VLDL-TAG PR and VLDL1-TAG PR than Controls (both p <0.05).  
Between diets In Controls, there was a higher PR of total VLDL-TAG (Fig. 1B.) and VLDL1-
TAG (both p <0.002) and higher concentration of VLDL1-TAG and cholesterol (both p 
<0.002) after the high versus low sugar diet (Tables 3 and 4). In contrast, in NAFLD there 
was no significant difference in the PR of total VLDL-TAG  or VLDL1-TAG, but a higher 
PR for VLDL2-TAG, IDL apoB, LDL2 apoB and LDL3 apoB (all p <0.05) (Table 4), and an 
increase in post-heparin hepatic lipase (p <0.05) (Supplementary Table 4) after the high 
versus low sugar diet. Although the TAG concentration in each individual fraction was not 
significantly different between diets in men with NAFLD, the sum of VLDL2, IDL, LDL2 
and LDL3 TAG was higher (p <0.05) (data not shown).  Oxidised LDL and sdLDL were 
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higher after the high sugar diet in men with NAFLD (both p <0.05) and Controls (both p 
<0.02) (Table 3).  
Palmitate kinetics and sources of fatty acids for VLDL1-TAG production  
Between groups Men with NAFLD were distinct from Controls by having a higher 
contribution of fatty acids to VLDL1-TAG PR from splanchnic fat on the high (both p <0.04) 
and low (both p <0.01) sugar diets (Fig 1C) (Supplementary Table 3). Men with NAFLD 
had a greater contribution of fatty acids from DNL to VLDL1-TAG PR than the Controls on 
the low sugar diet (p <0.01). 
Between diets Plasma NEFA concentration, palmitate PR and MCR were all higher in men 
with NAFLD (p <0.05, p <0.05, p <0.003) after the high versus low sugar diet 
(Supplementary Table 4). There was a greater contribution of fatty acids from splanchnic 
fat to VLDL1-TAG PR (p <0.02) after the high sugar diet in Controls (Fig 1C) but although 
increased in NAFLD it did not achieve significance (p=0.075). In NAFLD, there was a 
greater contribution of fatty acids from splanchnic fat to VLDL2-TAG PR (p <0.02) (Fig 1D) 
with no difference in Controls (between groups p<0.002). In Controls, there was a greater 
contribution of fatty acids from DNL (p <0.002) after the high sugar diet, but this was not 
evident in men with NAFLD. There was no significant difference in the contribution of 
systemic NEFA to VLDL1 and VLDL2-TAG PR between diets in either group (Fig 1C and 
D, Supplementary Table 3).   
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Discussion                                                                                                                                              
This study provides new evidence for the effects of a high sugar diet in increasing liver fat 
and the PRs of the atherogenic lipoproteins (IDL and LDL) in men with NAFLD. A high 
sugar diet produced a greater contribution of fatty acids from splanchnic fat to the production 
of VLDL1-TAG, in Controls whereas in NAFLD there was a greater contribution of fatty 
acids from splanchnic fat to the production of smaller more atherogenic VLDL2-TAG. 
The intake of sugar on the low sugar diet was close to the current recommendation for the 
intake of free sugars of no more than 5% total energy (NMES 6 ± 2% total energy or 586 kJ 
(140kcal) /day) [17, 18]. In contrast, the intake of sugar on the high sugar diet (NMES 26 ± 
7% total energy) was five times greater than this recommendation (2,721kJ (650kcals)/day), 
but within the upper 2.5
th
 percentile of a typical Western diet. Although there was a small 
difference in the intake of dietary fat between the iso-energetic diets, the overall metabolic 
response was consistent with the marked difference in intake of dietary sugar between the 
diets (20% of total energy).  
It has been well documented that hyper-energetic, high sugar diets increase liver fat in 
healthy men [19], but there is less evidence that iso-energetic high sugar diets exert the same 
effect. A weight maintaining high fructose diet (25% total energy) has been reported to 
increase liver fat by 137% in healthy men [20] and an iso-energetic diet containing sucrose 
sweetened regular cola increased liver fat by 132% in overweight subjects [21]. To our 
knowledge the current study is the first to show: a) higher liver fat in men with NAFLD 
following a high versus low-sugar iso-energetic diet and b) the effect of the high sugar diet on 
liver fat is greater than in Controls.  
There have been no studies to date on the effect of free sugar intake on VLDL kinetics in 
NAFLD. One study reported that VLDL-TAG PR in healthy subjects was higher after a 6-
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day hypercaloric diet enriched with fructose as a liquid supplement (25% total energy) than 
after a 6-day, low-fructose diet [22].  VLDL-TAG PR was also higher after a 2-week high 
carbohydrate, low fat diet, compared to a 2-week iso-energetic, low carbohydrate high fat diet 
in healthy subjects  [23]. In the present study, men with NAFLD on the low sugar diet, had a 
higher concentration and PR of large TAG-rich VLDL1 than Controls with low liver fat, as 
shown previously in men on habitual diets [24].  In the Controls, the PR and plasma 
concentration of large TAG-rich VLDL1 were higher on the high sugar diet compared to the 
low sugar diet. Moreover, the difference in PR of large TAG-rich VLDL1 between groups 
was removed on the high sugar diet, as the values in Controls approached that of men with 
NAFLD, possibly because the Controls also gained liver fat.   In men with NAFLD, although 
the PR of large TAG-rich VLDL1 was higher on the high sugar diet, this was not significant; 
however the PR of the smaller more atherogenic VLDL2 was significantly higher, suggesting 
an up-regulation of this pathway.  
Men with NAFLD had a higher DNL relative to the Controls after both diets, consistent with 
the increased contribution of DNL to hepatic and lipoprotein fat in men with NAFLD [6, 25]. 
However, this finding was only significant on the low sugar diet, since the contribution of 
DNL to VLDL-TAG increased significantly in Controls but not NAFLD after the high sugar 
diet. DNL made only minor contributions (4-8%) to VLDL1 and VLDL2-TAG production in 
both groups, and after both diets, as reported previously in healthy subjects [26]. DNL 
contributed approximately 12% of palmitate to VLDL-TAG in a previous study in NAFLD 
when measured over a comparable time period to the present study [6].  Previous studies have 
also shown that an 8 week diet with fructose-sweetened beverages, providing 25% of total 
energy, increased DNL, whereas glucose-sweetened beverages had no effect in healthy 
overweight participants [27].  Similarly, a 6-day high-fructose diet (25% total energy) 
increased DNL from 1.6 to 9.4% in VLDL-palmitate in healthy, normal weight men [28].   
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In the present study, there was no difference in the systemic contribution of fatty acids to 
VLDL1-TAG or VLDL2-TAG production between the diets, in both groups. This is perhaps 
surprising given the higher production and clearance rates of palmitate after the high sugar 
diet in NAFLD, which might be expected to result in increased delivery of NEFA to the liver.  
An increased contribution of fatty acids from splanchnic fat accounted for the majority of the 
higher VLDL1-TAG production on the high sugar diet in Controls and similarly in NAFLD 
the higher VLDL2-TAG, PR after the high sugar diet, was predominantly due to an increased 
contribution of fatty acids from splanchnic fat. This fat source consists of fatty acids from 
hepatic TAG storage pools and fatty acids from visceral adipose tissue, which drains directly 
into the liver via the portal vein. Hepatic TAG storage pools will expand in the fed, 
postprandial state, with an estimated 22% of dietary TAG being taken-up by the liver in 
chylomicron remnants [29], some of which will be stored and contribute to VLDL synthesis 
in the post-absorptive state [30].  The flux of NEFA from visceral adipose tissue has been 
estimated to be 17% of total NEFA delivery to the liver in obese men, but only 6% in lean 
men, and to correlate with visceral fat area by computer tomography [31].  However, since 
visceral fat was unaffected by the diets in the present study, this suggests that the relatively 
greater splanchnic contribution of NEFAs to VLDL-TAG production on the high sugar diet 
came from hepatic TAG storage pools. This would be consistent with the effect of dietary 
sucrose and fructose in augmenting postprandial lipaemia [32], and highlights the importance 
of postprandial TAG as a major source of lipid for the formation of an ALP via the 
accumulation of liver fat.  It also suggests that the intra-hepatic fat pool is not inert, and there 
is an active process of turnover between post-prandial and fasting states. 
Although the glycerol-3-phosphate pathway is the major pathway for TAG synthesis in the 
liver, an alternative pathway via monoacyglycerol acyltransferases (MGAT1-3) has been 
reported which is up-regulated in NAFLD (1). A possible source of monoacyglycerol for this 
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pathway is chylomicron remnants. Since an MGAT2-inhibitor has been shown to prevent 
carbohydrate induced fatty liver and suppress triglyceride synthesis and VLDL-secretion in 
mice fed a high sucrose very low fat diet (2), this pathway may contribute to the observed 
sugar induced VLDL2-elevation in the NAFLD subjects. 
The ability of plasma lipoproteins to infiltrate the artery wall is a function of their particle 
size. Smaller VLDL2 and IDL can cross the endothelial barrier and enter the arterial intima 
[33], while plasma IDL has been independently correlated with development of coronary 
atherosclerosis [34].  High sugar diets have been linked to the formation of oxidised LDL, 
and small, dense LDL (sdLDL) [27], a form of LDL with increased atherogenicity by virtue 
of its particle size, and susceptibility to undergo oxidative modification [35]. In our study, 
men with NAFLD had relatively higher production rates of IDL apoB, LDL2 apoB and LDL3 
apoB after the high sugar diet, suggesting an increased flux of VLDL into IDL and LDL. 
These findings were further supported by a higher activity of hepatic lipase, an enzyme with a 
major role in the re-modelling of VLDL to IDL and LDL [39], and LDL into oxidatively 
susceptible sdLDL, after the high sugar diet.  
In the present study, the two diets produced small, but remarkably similar effects on body 
weight in both groups, the high and low sugar diets being associated with a higher and lower 
weight (± 2kg), respectively.  Since this effects was the same in both groups, it suggests that 
the different responses to the diets between groups is unrelated to changes in body weight.  
In conclusion, men with NAFLD were shown to be more sensitive to the effects of a high 
sugar diet in terms of their greater response in liver fat, and production of an ALP, relative to 
Controls. This suggests that a high sugar intake may have a role in the pathophysiology of 
NAFLD. Reducing intake of dietary sugar to levels recommended by dietary guidelines (5% 
total energy) may produce changes in plasma lipoproteins of men with fatty liver that are 
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beneficial to their cardio-metabolic health.  
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Figure legends 
 
Figure 1: In NAFLD and controls a) the effect of a low (grey bars) and high sugar diet (black 
bars) on percentage liver fat b) the effect of a low (grey bars) and high sugar diet (black bars) 
on VLDL TAG production rate c) the contribution of fatty acids from systemic (black bar), 
splanchnic (white bar) and DNL (grey bar) to VLDL1 TAG production and d) the 
contribution of fatty acids from systemic (black bar), splanchnic (white bar) and DNL (grey 
bar) to VLDL2 TAG production. Significantly different between diets, * p<0.002; **p<0.02; 
# p<0.05; † p=0.08. Significantly different between NAFLD and controls on low sugar diet, ‡ 
p<0.01. Significantly different between NAFLD and controls on high sugar diet, § p<0.04.   
 
Figure 2: Schematic diagram showing the effect of a high sugar diet relative to a low sugar 
diet on lipoprotein metabolism in a) NAFLD and b) controls. Hatched arrows indicate 
significant changes. PR, production rate 
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                                    Table 1. Baseline characteristics.  
 NAFLD (n=11) Controls (n=14) 
Age y (range) 59 (49-64) 54(41-65) 
Body weight kg 90.0±2.2 89.7±2.4 
BMI kg/m
2
 28.9±0.3 28.4±0.5 
Waist circumference cm 104±2 104±1 
Liver fat % 17.2±2.7
b
 2.5±0.3 
Triacylglycerol mmol/l 1.89±0.27
a
 1.33±0.23 
Cholesterol mmol/l 5.91±0.25 5.51±0.28 
HDL cholesterol mmol/l 1.22±0.08 1.24±0.08 
Glucose mmol/l 5.73±0.11 5.46±0.12 
Systolic BP mmHg 131±7 134±3 
Diastolic BP mmHg 86±4.5 84±2.7 
Values are means ± SEM. Significant difference between liver fat groups                               
a
P <0.05, 
b
P<0.001. 
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    Table 2. Effects of high and low sugar diets on anthropometrics, and plasma lipids 
 
          NAFLD (n=11)       Controls (n=14) 
 High sugar Low sugar High sugar Low sugar 
Body weight (kg) 89.72.5 87.72.4c 88.92.8 86.72.9b 
BMI kg/m
2
 28.90.4 28.10.5 28.10.6 27.40.6 
Body fat
1  
% 27.60.8 26.30.8 24.40.7 23.60.9 
Plasma TAG
1
 mmol/l 2.050.24a 1.770.22a 1.330.15 1.130.08 
Plasma Cholesterol 
mmol/l 
5.590.33 5.240.30 5.100.25 4.820.26 
Plasma LDL-C mmol/l 3.560.29 3.390.27 3.430.19 3.210.21 
Plasma HDL-C mmol/l 1.180.09 1.130.07 1.160.07 1.130.08 
Plasma Glucose mmol/l 5.440.09 5.300.09 5.080.14 5.110.08 
Plasma Insulin mU/l 21.22.6 21.41.0 17.91.4 17.72.4 
HOMA-IR 5.20.7 5.00.2 4.00.3 4.10.6 
Values are arithmetic means ± SEMs unless stated otherwise. 
1
Geometric mean ± SEM. 
Significantly different between high and low liver fat groups 
a
P <0.01. Significant difference 
between high and low sugar diets (post-diet) within liver fat groups 
b
P <0.01, 
c
P <0.001
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                                 Table 3: Plasma lipoprotein fraction concentrations 
         NAFLD (n=11)      Controls (n=14) 
 High sugar Low Sugar  High sugar Low Sugar  
VLDL1-TAG  μmol/l 849109
e
 76197f 54767 38639c 
VLDL2-TAG μmol/l 14721 11010 10411 10414 
IDL-TAG μmol/l 615 525 545 6511 
VLDL1-Chol μmol/l 34576
e
 28349f 20726 12714c 
VLDL2-Chol μmol/l 16345 9713 8210 8013 
IDL-chol μmol/l 16753 8813a 8811 9916 
VLDL1-apoB mg/l 15.62.5 17.43.0 15.12.6 11.51.9 
VLDL2-apoB mg/l 12.52.1 11.61.5 13.13.4 11.02.7 
IDL-apoB mg/l 21.94.6 14.11.8b 20.25.0 20.95.8 
LDL2-TAG μmol/l 9910 9313 7512 718 
LDL3-TAG μmol/l 7912 728 607 656 
LDL2-chol μmol/l 101987 931106 78195 88182 
LDL3-chol μmol/l 122268 125260 114194 117245 
LDL2-apoB mg/l 30653 25540 25833 24932 
LDL3-apoB mg/l 56792 57498 57048 45953
a
 
Oxidised LDL μg/ml 5.220.0.36 4.070.55a 4.980.55 3.360.33b 
Small dense LDL μmol/l 1459210 1228175a 1043112 84878b 
Values are mean ± SEM. Ratios and 95% confidence interval of measurements that were 
significantly different are shown in Supplement Table 5. Significantly different between 
diets, 
a
P<0.05; 
b
P<0.02; 
c
P<0.002. Significantly different between NAFLD and control group 
on same diet, 
d
P<0.05; 
e
P<0.02; 
f
p<0.003 
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                                                Table 4: Lipoprotein kinetic data 
      NAFLD (n=11)    Controls (n=14) 
 High sugar Low Sugar  High sugar Low Sugar  
VLDL1-TAG production rate g/d 20.9±2.1 18.9±2.1
d
 16.6±1.4 12.4±1.16
c
 
VLDL1-TAG FCR pools/d 9.0±0.9
d
 9.5±1.0
d
 11.3±0.7 11.9±0.8 
VLDL2-TAG production rate g/d 4.90±0.59 3.70±0.43
a
 3.63±0.27 3.98±0.43 
VLDL2-TAG FCR pools/d 11.5±1.1 12.2±1.3 13.1±1.0 14.3±0.9 
VLDL1-apoB production rate mg/d 481±76 492±58 546±56 414±54 
VLDL1-apoB FCR pools/d 9.0±1.0 10.8±2.2 14.7±2.7 13.4±2.4 
VLDL2-apoB production rate mg/d 546±176 498±164 720±310 647±212 
VLDL2-apoB FCR pools/d 12.5±2.8 12.8±2.4 13.6±1.9 14.9±1.6 
Total VLDL-apoB production rate 
mg/d 
577±71 566±69 680±73 524±58 
IDL-apoB production rate mg/d 609±122 391±69
a
 740±159 737±213 
IDL-apoB FCR pools/d 9.5±1.9 8.7±0.9 12.2±1.1 12.1±1.2 
LDL2-apoB production rate mg/d 1452±277 858±101
a
 1075±109 1176±118 
LDL2-apoB FCR pools/d 1.59±0.25 1.35±0.23 1.59±0.24 1.74±0.26 
LDL3-apoB production rate mg/d 2069±388 942±278
a
 1518±237 1374±273 
LDL3-apoB FCR pools/d 1.01±0.15 0.46±0.09
c,d
 0.86±0.12 1.06±0.24 
Values are mean ± SEM. Ratios and 95% confidence interval of measurements that were 
significantly different are shown in Supplement Table 6. Significantly different between 
diets, 
a
P<0.05; 
b
P<0.02; 
c
P<0.002. Significantly different between NAFLD and control group 
on same diet, 
d
P<0.05; 
e
P=0.02; 
f
P<0.003. In the High liver fat group, n=9 for the IDL and 
LDL2 kinetic data and n=8 for the LDL3 kinetic data due to insufficient data for the model 
fit. 
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Figure 1: In NAFLD and controls a) the effect of a low (grey bars) and high sugar diet (black 
bars) on percentage liver fat b) the effect of a low (grey bars) and high sugar diet (black bars) 
on VLDL TAG production rate c) the contribution of fatty acids from systemic (black bar), 
splanchnic (white bar) and DNL (grey bar) to VLDL1 TAG production and d) the 
contribution of fatty acids from systemic (black bar), splanchnic (white bar) and DNL (grey 
bar) to VLDL2 TAG production. Significantly different between diets, * p<0.002; **p<0.02; 
# p<0.05; † p=0.08. Significantly different between NAFLD and controls on low sugar diet, ‡ 
p<0.01. Significantly different between NAFLD and controls on high sugar diet, § p<0.04.   
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Figure 2 Schematic diagram showing the effect of a high sugar diet relative to a low sugar 
diet on lipoprotein metabolism in a) NAFLD and b) controls. Hatched arrows indicate 
significant changes. PR, production rate 
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